Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials.
Mark LebwohlRichard Bruce WarrenHoward SofenShinichi ImafukuCarle F PaulJacek Cezary SzepietowskiLynda SpelmanThierry PasseronEleni VritzaliAndrew NapoliRenata M KisaAlex BuckSubhashis BanerjeeDiamant ThaҫiAndrew BlauveltPublished in: The British journal of dermatology (2024)
Deucravacitinib maintained efficacy and demonstrated consistent safety with no new safety signals observed through 2 years. (ClinicalTrials.gov identifier: NCT04036435).
Keyphrases